
Prelude Therapeutics Reports Q2 Financial Results and Key Clinical Developments
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, reported its financial results for the second quarter ending June 30, 2024. The company also provided significant …
Prelude Therapeutics Reports Q2 Financial Results and Key Clinical Developments Read More